Company profile
LIGAND PHARMACEUTICALS INC
NASDAQ:LGNDBiotechnology: Pharmaceutical Preparations
Drug pipeline (3)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| SITAVIG | approved | — | 1 | approved |
| LGD-6972 | phase2 | — | 4 | no active trials |
| VK-2809 | phase2 | — | 3 | completed, withdrawn |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (21)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02672839 | phase1 | completed | 2016-02-01 | 2016-05-01 | Ligand Pharmaceuticals | A Comparison Study of the Bioavailability of a Capsule Formulation of LGD-6972 to an Oral Solution Formulation |
| NCT00635232 | phase2 | completed | 2008-03-01 | 2008-11-01 | Ligand Pharmaceuticals | A Study To Evaluate The Dose-Related Efficacy and Safety of PS433540 in Subjects With Hypertension |
| NCT02851849 | phase2 | completed | 2016-09-01 | 2017-06-01 | Ligand Pharmaceuticals | A Study of LGD-6972 in Patients With Type 2 Diabetes Mellitus |
| NCT00002212 | phase2 | completed | — | — | Ligand Pharmaceuticals | A Study of Targretin Capsules in Patients With AIDS-Related Kaposi's Sarcoma |
| NCT00522925 | phase2 | completed | 2007-08-01 | 2008-04-01 | Ligand Pharmaceuticals | A Trial to Evaluate the Safety and Efficacy of PS433540 to Treat Hypertension |
FDA applications (1)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| NDA 203791 | 2013-04-12 | NDA | LIGAND PHARMACEUTICALS INC | |||||
Loading… | ||||||||